Pharmaceuticals, Corporate Crime and Public Health

Pharmaceuticals, Corporate Crime and Public Health

Graham Dukes, John Braithwaite and J. P. Moloney

The pharmaceutical industry exists to serve the community, but over the years it has engaged massively in corporate crime, with the public footing the bill. This readable study by experts in medicine, law, criminology and public health documents the problems, ranging from false advertising and counterfeiting to corruption waste and overpricing, with unacceptable pressures on doctors, politicians, patients and the media. Uniquely, the book goes on to present a realistic and worldwide solution for the future, with positive policies encouraging honest dealing as well as partial privatization of enforcement and greater emphasis on creative research to develop the medicines that society needs most.

Chapter 3: Aggressive or misleading promotion

Graham Dukes, John Braithwaite and J. P. Moloney

Subjects: law - academic, biotechnology and pharmaceutical law, health law, social policy and sociology, health policy and economics

Extract

It is simple enough to declare that the acceptability of drug advertising and promotion must be assessed in the light of the true facts. However, the quest for a definition of what constitutes truth is at least as frustrating where most medicines are concerned as in any other field. As noted in Chapter 1, even the picture of a drug’s safety and efficacy that is drawn by a committee of experts at the moment that it is licensed is only a provisional sketch that will necessarily be supplemented by experience in the field as time – sometimes a long time – goes by. Acetylsalicylic acid (Aspirin) was used without reservation to treat feverish infants from the time of the drug’s introduction in 1899 until, many decades later, a causal link between such treatment and the serious complication known as Reye’s syndrome was suspected and later confirmed (Section 1.7). More than 40 years on, even that intensively studied link remains an indistinct and irregular one, perhaps involving some genetic predisposition; the debate on selecting the safest treatment for children with fever therefore continues. The fact is that the evidence in these matters is continuously evolving and often the subject of controversy. Even where a degree of certainty has been attained, it is likely to involve qualified conclusions.

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information